Inhibrx Biosciences Financial Statements
NASDAQ: INBXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Inhibrx Biosciences revenue and earnings
In fiscal 2025, Inhibrx Biosciences generated $1.3 million in revenue, up 550.0% from fiscal 2024. Inhibrx Biosciences reported a net loss of $140.1 million, compared with net income of $1.69 billion a year earlier. Operating margin was -10386.5%.
Diluted earnings per share came in at -$9.04, down from $112.62. Over the last 2 fiscal years, INBX's revenue has grown at a -15.0% compound annual rate (a contraction).
Summary generated from market data by MetaCap's automated system. Methodology
Inhibrx Biosciences income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 |
|---|---|---|---|
| Revenue | 1.30M | 200.00K | 1.80M |
| Revenue growth (YoY) | +550.00% | -88.89% | — |
| Operating Expenses | 136.32M | 331.65M | 221.02M |
| Research & Development | 113.03M | 203.74M | 191.64M |
| Operating Income | -135.03M | -331.45M | -219.22M |
| Interest Expense | 12.20M | 13.49M | 31.84M |
| Other Income (Expense) | -5.03M | 2.02B | -20.50M |
| Pretax Income | -140.05M | 1.69B | -239.72M |
| Income Tax | 2.00K | 2.00K | 3.00K |
| Net Income | -140.06M | 1.69B | -241.36M |
| Net Income growth (YoY) | -108.30% | — | — |
| EPS (Basic) | -9.04 | 114.01 | -20.48 |
| EPS (Diluted) | -9.04 | 112.62 | -20.48 |
| Shares Outstanding (Basic) | 15.49M | 14.80M | 11.78M |
| Shares Outstanding (Diluted) | 15.49M | 14.98M | 11.78M |
| EBITDA | -132.54M | -329.16M | -218.03M |
| Operating Margin | -10386.54% | -165724.00% | -12178.94% |
| Net Margin | -10773.46% | 843786.00% | -13408.94% |
This table shows 3 annual periods of Inhibrx Biosciences's income statement, from FY 2025 back to FY 2023, across 16 line items including revenue, operating expenses, research & development. Values in USD; B = billions, M = millions. Fiscal periods follow INBX's reporting calendar. What is a income statement?